Red Light Therapy for Lichen Sclerosus & Planus

Lichen sclerosus and lichen planus are chronic inflammatory skin conditions that cause significant discomfort and can be difficult to manage long-term. Both conditions involve immune-mediated inflammation, which makes the anti-inflammatory properties of red light therapy theoretically relevant. However, the direct clinical evidence is extremely limited, and this page aims to provide an honest, evidence-based assessment rather than false hope.

Understanding the Conditions

Lichen Sclerosus

Lichen sclerosus (LS) is a chronic inflammatory dermatosis that most commonly affects the anogenital skin, though it can occur anywhere on the body. It predominantly affects postmenopausal women, though men and children can also be affected.

Key features:

White, atrophic patches of skin that become thin, crinkled, and fragile
Intense itching (pruritus), often severe enough to disturb sleep
Pain, particularly with intercourse (dyspareunia) when genital skin is affected
Skin splitting and fissuring with minor trauma
Progressive scarring that can alter genital anatomy — labial fusion, clitoral hood adhesion, and introital narrowing in women; phimosis in men
A small but established risk of squamous cell carcinoma (approximately 4–5% lifetime risk in vulvar LS)

Pathophysiology: LS is an autoimmune condition involving T-cell-mediated inflammation targeting the dermal-epidermal junction. The inflammatory infiltrate (predominantly CD4+ and CD8+ T lymphocytes) damages the basal layer of the epidermis and upper dermis, leading to collagen homogenisation — the replacement of normal collagen architecture with dense, hyalinised collagen that is structurally and functionally abnormal. This process produces the characteristic white, atrophic appearance.

Standard treatment: High-potency topical corticosteroids (clobetasol propionate 0.05%) remain the first-line treatment. They are effective for symptom control in the majority of patients but do not cure the condition, and long-term use raises concerns about skin thinning — though this risk is lower in genital skin than often assumed.

Lichen Planus

Lichen planus (LP) is a chronic inflammatory condition that can affect the skin, mucous membranes (oral, genital), hair follicles, and nails. Unlike LS, LP has a broader anatomical distribution.

Key features:

Cutaneous LP: Flat-topped, violaceous (purplish) papules and plaques, often with fine white lines on the surface (Wickham striae). Typically affects the wrists, ankles, lower back, and shins.
Oral LP: White, lacy patches (reticular pattern) or painful erosions on the buccal mucosa, gingiva, or tongue. Affects approximately 1–2% of the adult population.
Vulvovaginal LP: Erosive, painful lesions that can cause significant sexual dysfunction and progressive vaginal stenosis.
Lichen planopilaris: Scarring alopecia affecting the scalp.

Pathophysiology: LP involves a cytotoxic T-cell attack on basal keratinocytes. CD8+ T lymphocytes release cytokines (IFN-gamma, TNF-alpha) and directly induce apoptosis of basal epithelial cells. This is a more aggressive inflammatory process than LS and results in erosive tissue destruction rather than atrophy.

Standard treatment: Topical and systemic corticosteroids, calcineurin inhibitors (tacrolimus, pimecrolimus), retinoids, and immunosuppressive agents for severe or refractory cases.

The Theoretical Case for Red Light Therapy

Anti-Inflammatory Mechanisms

Both LS and LP are driven by T-cell-mediated inflammation, and PBM has documented immunomodulatory effects:

TNF-alpha reduction: PBM reduces TNF-alpha production in activated immune cells (Hamblin, 2017, BBA Clinical, 6:113-124). TNF-alpha is a key cytokine in both LS and LP pathogenesis.
NF-kappaB pathway modulation: PBM modulates the NF-kappaB signalling pathway, which orchestrates the inflammatory response in autoimmune skin conditions (Chen et al., 2011, PLoS ONE, 6(10):e25921).
T-cell modulation: PBM has been shown to influence T-cell cytokine profiles, potentially shifting from a pro-inflammatory Th1 response towards a more balanced immune state.

Tissue Repair

Collagen remodelling: PBM stimulates fibroblast activity and collagen synthesis, which could theoretically improve the disordered collagen seen in LS (though whether PBM can reverse established collagen homogenisation is unknown).
Wound healing: For erosive LP, PBM’s wound-healing effects (enhanced keratinocyte migration and proliferation) could support healing of mucosal erosions.
Angiogenesis: PBM promotes new blood vessel formation, potentially improving perfusion in atrophic tissue.

The Critical Gap

While these mechanisms are plausible, plausibility is not evidence. The inflammatory processes in LS and LP are chronic, autoimmune, and deeply embedded. Whether the relatively modest immunomodulatory effects of PBM can meaningfully alter the disease course in conditions that often require potent corticosteroids or systemic immunosuppression is an open question — and the honest answer is that we do not know.

What the Clinical Evidence Shows

As with many inflammatory skin conditions, the most relevant light-based evidence involves photodynamic therapy (PDT), not standalone PBM:

Sotiriou et al. (2009, Journal of the European Academy of Dermatology and Venereology, 23(11):1353-1354) reported a case of vulvar LS treated with ALA-PDT (5-aminolaevulinic acid with 630 nm red light activation). The patient showed clinical improvement after 3 sessions, with reduced pruritus and improved skin texture. However, this is a single case report.

Olejek et al. (2010, Photodiagnosis and Photodynamic Therapy, 7(3):180-183) treated 10 women with vulvar LS using ALA-PDT. After 10 sessions, 8 of 10 patients showed histological improvement (reduced inflammation, improved collagen structure). Symptom scores (pruritus, burning) improved significantly.

Regarding oral LP: Several studies have examined PDT for erosive oral lichen planus with mixed results. Aghahosseini et al. (2006, Journal of Clinical Laser Medicine and Surgery, 24(4):207-211) reported improvement in oral LP lesions after methylene blue-mediated PDT.

Critical caveat: PDT uses a photosensitiser that fundamentally changes the mechanism of action. These results cannot be extrapolated to standalone red light therapy.

Standalone PBM Evidence

No published RCT has examined standalone red light therapy (without photosensitiser) for either lichen sclerosus or lichen planus.

There is one area of tangential evidence worth noting:

Cafaro et al. (2014, Lasers in Medical Science, 29(4):1463-1466) studied low-level laser therapy (diode laser, 645 nm, 100 mW) for oral lichen planus in 30 patients. Patients received LLLT to erosive oral LP lesions twice weekly for 4 weeks. The treatment group showed statistically significant reduction in pain scores and lesion size compared with baseline, with improvement persisting at 1-month follow-up.

This is the most directly relevant study, though it was a single-centre study without a sham control group, and it specifically addressed oral LP rather than cutaneous or vulvar disease.

Jajarm et al. (2011, Photomedicine and Laser Surgery, 29(6):421-425) compared LLLT (630 nm, 120 mW, 4 J/cm2) with topical corticosteroid for oral LP in 28 patients. Both groups showed improvement, with no statistically significant difference between treatments at 8 weeks. The authors suggested LLLT could be a steroid-sparing alternative for oral LP.

Practical Considerations

If You Want to Try PBM

Given the very limited evidence, any use of PBM for lichen sclerosus or lichen planus should be considered experimental and should not replace standard treatment. If you wish to trial PBM as an adjunct:

For lichen sclerosus (vulvar/genital):

Continue your prescribed topical corticosteroid
Use a targeted device or small panel delivering 630–660 nm red light
Irradiance: 20–40 mW/cm2
Dose: 4–6 J/cm2 per session
Frequency: 3–5 times per week
Duration: Trial for 8–12 weeks before assessing benefit
Device positioning: At a distance of several inches to avoid direct contact with sensitive or eroded skin

For oral lichen planus:

Continue prescribed treatment
Intraoral light delivery requires a specialised device (dental phototherapy probes or narrow-beam wands) — standard face masks and panels cannot effectively treat oral mucosal surfaces
Parameters from the Cafaro study: 645 nm, 2–4 J/cm2 per lesion, twice weekly

For cutaneous lichen planus:

Use a panel or targeted device delivering 630–660 nm red + 830–850 nm NIR
Irradiance: 20–40 mW/cm2
Dose: 6–10 J/cm2 per session
Frequency: 3–5 times per week
Treat affected areas directly; include a margin of perilesional skin

Important Warnings

Do not discontinue prescribed treatment (especially topical corticosteroids for LS) in favour of red light therapy. LS requires ongoing treatment to prevent progression and reduce malignancy risk.

Monitor for changes. Both LS and LP can undergo malignant transformation (squamous cell carcinoma in LS; oral SCC in erosive oral LP). Regular clinical surveillance by a dermatologist or gynaecologist is essential regardless of any adjunct therapy you are using.

Genital skin is sensitive. Start with lower doses and shorter sessions when treating vulvar or genital LS, and increase gradually. Avoid contact devices on eroded or fissured skin.

The Bottom Line

The theoretical rationale for red light therapy in lichen sclerosus and lichen planus is coherent — both conditions involve chronic inflammation that PBM may modulate. However, the clinical evidence is extremely limited. The only directly relevant studies involve oral lichen planus treated with LLLT, showing modest benefit in small, uncontrolled trials.

For vulvar lichen sclerosus — the form of the disease that causes the most suffering and has the most significant complications — there is no published evidence for standalone PBM. The PDT studies (using photosensitisers) show more promise but represent a fundamentally different intervention.

If you choose to trial PBM for either condition, treat it as a speculative adjunct to proven therapy, not a replacement. Continue your prescribed treatment, monitor your condition carefully, and set realistic expectations. The honest assessment is that we simply do not yet know whether PBM provides meaningful benefit for these conditions, and the evidence needed to answer that question has not yet been generated.